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Motor neuron diseases (MNDs) are neuromuscular disorders where the spinal
motor neurons–either the cell bodies themselves or their axons–are the
primary cells affected. To date, there are 120 different genes that are lost or
mutated in pediatric-onset MNDs. Most of these childhood-onset disorders,
aside from spinal muscular atrophy (SMA), lack viable therapeutic options.
Previous research on MNDs has focused on understanding the pathobiology of
a single, speciﬁc gene mutation and targeting therapies to that pathobiology.
This reductionist approach has yielded therapeutic options for a speciﬁc
disorder, in this case SMA. Unfortunately, therapies speciﬁc for SMA have
not been effective against other pediatric-onset MNDs. Pursuing the same
approach for the other deﬁned MNDs would require development of at
least 120 independent treatments raising feasibility issues. We propose an
alternative to this this type of reductionist approach by conceptualizing MNDs
in a complex adaptive systems framework that will allow identiﬁcation of
common molecular and cellular pathways which form biological networks
that are adversely affected in early-onset MNDs and thus MNDs with
similar phenotypes despite diverse genotypes. This systems biology approach
highlights the complexity and self-organization of the motor system as well
as the ways in which it can be affected by these genetic disorders. Using this
integrated approach to understand early-onset MNDs, we would be better
poised to expand the therapeutic repertoire for multiple MNDs.
KEYWORDS

motor neuron disease, network biology, complexity, therapeutics development, spinal
muscular atrophy, peripheral neuropathy, amyotrophic lateral sclerosis

Introduction
Neuromuscular diseases (NMDs) result in chronic, severe disability as well as
early mortality and a high burden of disease. They also display clinical and genetic
heterogeneity; in fact, there are currently 1,079 distinct NMDs and 608 known genes
associated with these disorders (1). While each NMD is rare, they collectively have a
prevalence of about 1 in 700. Motor neuron diseases (MNDs) are a group of NMDs
where the spinal motor neurons–either the cell bodies themselves or their axons–are
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examines the interactions and interdependencies between
biomolecular components within a system, as opposed to the
components themselves (10). Examination of these networks
within motor neurons provides important insights into their
function as well the consequences of a disease-associated
mutation within one of the components. This characterization
can be completed at different levels including gene regulatory
networks, protein-protein interaction networks as well as
metabolite analysis (11, 12).
Interrogating the changes in gene regulatory networks
has provided important insights into how motor neurons
are affected in early-onset MNDs. A genetic screen of
modifiers of Smn dependent lethality in Drosophila melanogaster
identified pathways involved in alternative splicing, neuronal
differentiation, axonal guidance and neuromuscular junction
maturation as modifier of the SMA-like phenotype (13).
Using a genetic screen on a fruit fly model of ALS8–caused
by loss of functional VAMP-associated protein B (VAPB),
genes associated with vesicular trafficking, endosome trafficking
and cell proliferation were identified as modifiers of disease
phenotype (14). Pathways involved in cell proliferation and
neuronal development were differentially affected in SMA
mouse motor neurons derived from embryonic stem cells
(15). Network analysis of presymptomatic SMA mouse spinal
cord transcriptomes showed impairment of neurotrophin
signaling pathways (16). Comparing the transcriptomes of
motor neurons vulnerable to neurodegeneration against those
which are resistant to neurodegeneration in wild-type as well
as SMA mice revealed enrichment in pathways associated
with ribosome biosynthesis, translation, the extracellular matrix
and cell adhesion (17, 18). Kline et al. (18) compared
their list of transcripts that were differentially vulnerable to
neurodegeneration with independent screens for motor neuron
vulnerability transcripts (19–21) and identified 595 transcripts
altered in the same direction between at least two of the
modifier screens. Network analysis showed enrichment of
pathways involved in neuronal function and synaptogenesis. A
comparison of the transcriptomes of SMA spinal motor neurons
that are vulnerable to neurodegeneration against those motor
neurons which are resistant to degeneration (ocular motor
neurons) revealed networks associated with neurotransmitter
release, neuronal survival, oxidative stress and apoptosis as
modifiers of neurodegeneration associated with the loss of
functional SMN (22).
Weighted correlation network analysis (WGCNA) is an
approach to identify disease-related networks and hubs from
different datasets (23). When comparing the transcriptomes
from SMA patients with varying degrees of phenotypic
severities, WGCNA identified transcripts associated with tumor
necrosis factor α (TNFα)-mediated regulation of neural, cardiac
and bone development (24). These target transcripts showed
similar disease severity-dependent differential expression in
mouse models for SMA. Large-scale WGCNA of blood

the primary cells affected (2). Those MNDs with early onset
include spinal muscular atrophies (SMAs), juvenile forms of
amyotrophic lateral sclerosis (ALS), distal hereditary motor
neuronopathies (dHMNs) and axonal–or type 2–CharcotMarie-Tooth (CMT) disease. There are approximately 120 genes
to date that are lost or mutated in pediatric-onset MNDs. Most
of these childhood-onset disorders, aside from proximal SMA,
lack viable therapeutic options.
The majority of research on MNDs has focused on a single
disorder, like SMA, and to develop a single-target therapeutic
strategy specific for that disorder. This reductionist approach
has been applied to understanding disease pathogenesis and
therapeutics development as well as for care (3). This approach
to SMA has been successful in that there are currently 3
therapies–nusinersen (4, 5), risdiplam (6) and onasemnogene
abeparvovec (7)–that are approved for clinical use which
target SMN expression, either by SMN1 gene replacement or
modulating the alternative splicing of the orthologous SMN2
gene. While these options are likely to have significant positive
impacts on the quality of life of many patients with SMA, not
all SMA patients respond positively to these clinically approved
therapies and the length of therapeutic benefit in these patients
is not known (8). For maximal therapeutic benefits these agents
need to be administered at the early stages of disease progression.
These approved therapies lessen the severity of disease in SMA
but, unfortunately, do not completely cure children with this
disorder raising the issue of whether combination therapies
could improve outcomes further. Importantly, therapies specific
for SMA have not been effective against other pediatric-onset
MNDs thereby limiting their benefits for early-onset MNDs in
general. These issues suggest that there needs to be a broadening
of concepts related to pathophysiology of MNDs with a view that
this will lead to alternative research approaches and ultimately
the development of novel therapies.
While each disorder is caused by a loss of or mutation
in a specific gene, there are commonalities with respect to
mechanisms of disease within the various early-onset MNDs
as well as within other neurodegenerative diseases (9). Motor
units are functionally linked entities composed of spinal motor
neurons that innervate skeletal muscles as well as regulatory
interneurons projecting from these target muscles. The question
we pose in this article is whether motor units can be
conceptualized as complex adaptive systems and whether there
are pathophysiologic and therapeutic advantages to a complex
adaptive system conceptualization.

Motor neuron diseases and
biological networks
The commonalities amongst the genetically distinct earlyonset MNDs can be understood holistically using a network
biology, or network medicine, approach. Network biology
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stress) response, spliceosome assembly and function as
well as mRNA processing. They also found that energy
metabolism processes, mainly those related to glycolysis and
gluconeogenesis, were unique to the type 2 CMTs. Comparison
of the transcriptomes of different cellular models of type 2
CMT motor neurons {CMT2A2A [MFN2(R94Q)], CMT2E
[NEFL(P8R)], CMT2F [HSPB1(G84R) and HSPB1(P182L)]
and CMT2L [HSPB8(K141N)]} revealed overrepresentation of
mitochondrial respiratory chain and axon guidance networks
(36). Interestingly, the differential overrepresentation of these
networks is unique to motor neurons.
There is strong overlap and interconnectivity between the
SMA and ALS PPI networks (37). One of the first common
links between PPIs for SMA and ALS was described in 2017
where survival motor neuron 1 (SMN1) and the ALS-associated
proteins FUS RNA binding protein (FUS), TAR DNA binding
protein 43 (TDP43) and senataxin (SETX) were identified as
shared components with the RNA metabolism network (38).
Interactome analyses of the ALS-associated proteins FUS, EWS
RNA binding protein 1 (EWSR1), TAT-box binding protein
associated factor 15 (TAF15) and matrin-3 (MATR3) revealed
a common association with the U1 snRNP assembly network
as well as the RNA polymerase II network (39). The U1
small ribonucleoprotein (snRNP) assembly network is also
linked to SMA. This group also demonstrated five proteins
linked to SMA– SMN1, activating signal cointegrator 1 complex
component 1 (ASCC1), exosome component 8 (EXOSC8) and
heat shock protein B1 (HSPB1)–were integral components of
this RNA polymerase II network (40). Comparative proteomics
between SMA and ALS biosamples revealed alterations in energy
homeostasis, protein metabolism and oxidative stress response
that were present in both disorders (41). Kubinski and Claus
(42) used network analysis to show that the ALS-linked protein
Cu/Mn-dependent superoxide dismutase (SOD1) and profilin-1
(PFN1) serve as intermodular nodes connecting motor neuron
disease pathogenesis and actin cytoskeleton dynamics.
Modifier genes can regulate disease phenotype without
necessarily causing the early-onset MNDs. SMN2 is an extremely
well characterized modifier gene for SMA as increasing SMN2
copy number lessens the disease severity [reviewed in (43)].
Plastin-3 (PLS3)–one of the first SMN2-independent modifier
genes identified for SMA–mRNA levels were found to be
higher in females with milder SMA than those siblings with a
more severe SMA clinical presentation (44–49). The modifier
capability of PLS3 for SMA was subsequently found to be
incompletely penetrant within the SMA population as well as
within animal models (47, 50–53). Other putative SMA modifier
genes identified to date include neurocalcin-D (NCALD) (54),
Tolloid-like 2 (TLL2) (55) and neuritin 1 (NRN1; cpg15)
(48, 56). When comparing the clinical variability between
CMT4K, ganglioside-induced differentiation-associated protein 1
(GDAP1)-linked patients, junctophilin-1 (JPH1) was identified
as a modifier of disease phenotype by altering mitochondrial

transcriptomes from ALS patients revealed enrichment of
pathways involved in neurodegeneration and inflammation
(25). The complement activator dehydrogenase/reductase (SDR
family) 4 (DHRS4) was identified as a hub gene for ALS1 by
comparing the transcriptomes of SOD1 (G93A) mouse spinal
cords using WGCNA (26). This analysis suggests the role of the
complement cascade in motor neuron degeneration in ALS.
WGCNA can also be used to distinguish disease-specific
network regulation between allelic disorders. For examples ALS4
and ataxia with oculomotor ataxia type 2 (AOA2) are clinical
distinct early-onset neurodegenerative diseases disorders but are
caused by mutations in senataxin (SETX) (27, 28). WGCNA
of fibroblast transcriptomes with ALS4-specific SETX mutation
against those with an AOA2-specific SETX mutation identified
networks which are unique to either disorder (29). Specifically,
networks associated with the regulation of RNA metabolism
were overrepresented in ALS4 transcriptomes. Comparison of
spinal cord and cerebellum transcriptomes from two different
mouse models for ALS4 [expressing either SETX (R2136H) or
SETX (L389S) mutant transgenes] identified overrepresentation
of pathways involved in synaptic signaling and nervous system
development (30). Interestingly, these pathways were not
enriched in a mouse model for AOA2.
In addition to gene regulatory network analysis, important
insights into the pathogenesis of early-onset motor neuron
diseases can be gained from the analysis of disease-associated
protein-protein interaction (PPI) networks. When comparing
the protein-protein interactomes between ALS and ALS linked
with frontotemporal dementia (ALS-FTD), there were common
hub proteins between these two types of motor neuron disease
but the enrichment profiles around these hubs were distinct
between ALS and ALS-FTD (31). This PPI network analysis
identified ubiquitin-C as a common downstream target amongst
these disorders. Jensen et al. (32) recently compiled a PPI
network analysis for ALS and identified key modules associated
with disease phenotype–oxidative stress, energy metabolism,
proteosome dysfunction and mRNA processing defects. Some
of these modules are commonly observed in other forms of
neurodegeneration but other networks, like oxidative stressinduced protein misfolding, were found to be unique to ALS.
A similar analysis of the ALS PPI networks showed similar
modules and identified the cell cycle regulatory protein CDC5L
as a stabilizer of these interactomes (33).
Biological networks have also been identified amongst
disorders affecting motor neuron axons, such as type 2 CMTs
and hereditary spastic paraplegias (HSPs). Network analysis of
all CMT-related genes–including those linked to demyelinating
peripheral neuropathy–identified pathways involved in
myelination, axonal function, mitochondrial metabolism
and autophagy as key pathways in CMT pathogenesis (34).
Bis-Brewer et al. (35) identified common modules between
the PPI networks of these axonopathies. These common
modules include protein misfolding (endoplasmic reticulum
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damaged motor neurons for microglial degradation (78).
Microglial activation can be attenuated in SMA mice with
the sigma-1 receptor agonist PRE-084 (79). PRE-084 can also
attenuation deafferentation in SMA motor neurons. Future
studies need to fully characterize how alterations in glial–both
astroglial and microglial–reactivity can interact with and affect
motor neuron biological networks.

calcium channel activity (57). Loss of or mutation in neuropilin1 (NRP1), the voltage-gated sodium channel NaV1.6 (SCN8A)
or neuronal cell adhesion molecule (NRCAM) are linked to
disease severity in CMT4C–which is mediated by mutation in
the glycyl-tRNA synthetase (GARS) gene (58, 59).
In addition to identifying common molecular pathways
amongst early-onset MNDs, network analysis can provide
important insights into therapeutic options. Using this systems
network approach, ubiquitin-C was identified as a common
therapeutic target between the various genetic forms of
ALS and ALS-FTD (31). Gene delivery of UCHL1–a key
enzyme controlling the amount of ubiquitin-C present in
polyubiquitin chains on proteins–to upper motor neurons
improves motor neuron phenotype in multiple models of ALS
(60). Future studies will demonstrate the therapeutic potential
of UCHL1 modulation in multiple early-onset MNDs as well
as identify via network analysis additional common targets for
therapeutic benefit.
Sensory inputs onto motor neurons are also affected in
early-onset MNDs. Mentis et al. (61) showed that SMA motor
neurons lose their proprioceptive sensory inputs, referred to
as deafferentation, during early stages of disease progression
in the SMN17 SMA mouse model. Deafferentation of motor
neurons has been confirmed in a different mouse model for SMA
(62). This loss of sensory input to motor neurons is a result
of misregulation of ubiquitin-like modifier-activating enzyme-1
(UBA1) and GARS (63). Both genes have been implicated in
early-onset MNDs. It remains to be determined whether loss
of sensory inputs to motor neurons is universal to early-onset
MNDs. The biological networks implicated in deafferentation of
motor neurons need to be more fully characterized to determine
how they are affected in early-onset MNDs.
Biological networks affected by early-onset MNDs involve
glial cells in addition to motor neuron [reviewed in (64)].
Reactive gliosis was observed in the spinal cords of patients
with type I SMA (65, 66) as well as in pathological specimen
from CMT2A2 patients (67). Reactive astrogliosis occurs
during the end stage of disease progression in SMA mouse
models and restoration of SMN in SMA astrocytes reduces
the release of proinflammatory cytokines (68, 69). SMA
reactive astrocytes show altered calcium homeostasis and
hyperactivation of Notch signaling (70, 71). SMN-deficient
reactive astrocytes alter the release of regulatory agents like
MCP-1 (monocyte chemoattractant protein-1) and miR-146a
which promotes motor neuron loss (72, 73). SMA astrocytes also
show diminished ability to form and maintain neuromuscular
synapses (74).
Microglia are activated within the spinal cord during
early-onset MNDs. Microglial activation has been observed in
mouse models for SMA (68, 75) as well as for CMT2K (76).
SMA microglia acquire a reactive phenotype that enhances
inflammatory responses in the spinal cord (77). Classical
complement C1q pathways are activated in SMA to mark
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Lower motor units as complex
adaptable systems
The previous section highlights the observation that a
genetic mutation alters multiple networks in a way in which
there is biological convergence with similarities in emergent
phenotypes. We suggest that the convergences are critically
important components of disease pathophysiology that deserve
explicit study. A strong theoretical framework underlying these
sorts of studies is that of complex adaptive systems.
A generalizable description of complex adaptive systems
(Figure 1A) is that they are collections of relatively simple
agents that have the property that they can aggregate, so that
collections of agents can form meta-agents (and meta-metaagents etc. . . ) with hierarchical higher-order structure (80–
82). These aggregates interact non-linearly, so that aggregate
behavior of a collection of agents is qualitatively different from
the behavior of the individual agents, e.g., the behavior of a
collection of genes is qualitatively different to the behavior of
a collection of neurons. The interactions among agents mediate
flows of materials or information. Finally, the agents are typically
diverse with distinct specialties that are optimized through
adaptation to selective pressures in their environments. There
are an enormous number of system types that meet these criteria
e.g., economies, ecologies, traffic networks and brains (83,
84). Given the commonalities in underlying structure of these
systems, there are generalizable strategies for understanding
and manipulating such systems. The complex adaptive systems
approach to biology is rather new, but the ideas resonate
with many scientists and therefore studies designed within
this framework are becoming more common. Our aim is to
operationalize these general concepts to MNDs and explore how
this would change current paradigms.
Motor units can easily be seen as complex adaptive
systems. At the lowest hierarchical layer there is molecular
diversity amongst spinal motor neurons (85). Networks
of gene expression defined by transcriptomics non-linearly
influence the emergence of spinal motor neurons that differ
by temporal development and differentiation as well as by
spatial organization within the body (86). Importantly, it is not
the function of a single gene that determines motor neuron
fate, but rather the interactome of genes and the non-linear
hierarchical interactions of proteins, neurons and networks that
define the emergent phenotypes we define a motor function.
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with ALS as the disease progresses (97). There is a relationship
between the frequency of these fasciculations and muscle type
in ALS patients (98). Muscle fasciculations in ALS may be an
early indicator of motor neuron dysfunction (99) although their
usefulness as an indicator for motor unit dysfunction has been
questioned (100, 101).
Are fasciculations observed in early-onset MNDs? Clinical
characterization of SMA population found the presence of
tremors in some patients (102–104). Muscle fasciculations have
also been observed in men with spinal and bulbar muscular
atrophy (SMAX1) with a possible relationship with disease
severity, triplet repeat length with the androgen receptor (AR)
gene and testosterone levels (105). As with cases of adult ALS,
these fasciculations are not always present in patients with
early-onset MNDs. Further detailed analyses of fasciculations in
patients with early-onset MNDs will provide important insights
into the network level drivers of disease progression.

FIGURE 1

Flow of information in a complex system in motor neuron
health, disease and therapeutic intervention. (A) In a healthy
motor unit–lower motor neurons, interneurons and the muscle,
activation of a signal (yellow triangle) leads to the stimulation of
multiple agents (blue circles) that are interconnected into
collection of aggregates known as meta-agents to form a
hierarchical higher-order structure. The aggregates interact
non-linearly to elicit a response (green star) whose behavior is
quantitatively different from the individual agents. (B) Upon the
loss of or alteration in an agent (in this case, an early-onset MND
represented by the red X), the behavior of the aggregated
meta-agents is altered and the ﬂow of information is blunted.
(C) A therapeutic agent (purple arrow) can activate one of the
undamaged agents which would, in turn, activate the unaffected
parts of the hierarchical aggregate and partially compensate for
the diminished ﬂow of information resulting from the altered
agent.

Multi-modal and multi-indication
therapeutics for motor neuron
diseases

During development, spinal motor neurons differentiate into
compact anatomic units known as motor neuron pools that
connect to specific and unique muscle (87). The composition
of these motor neuron pools is heterogeneous based on the
types of myofibers they innervate. The diversity of motor
neuron subtypes as well as their formation into pools suggests
multiplicity and self-organization. Mathematical modeling of
the spinal monosynaptic reflex unit as well as the regulatory
interneurons demonstrate functional self-organization of the
motor unit (88, 89). Thus, motor units can be characterized by
non-linear interactions between multiple components operating
on multiple temporal and spatial scales (90). High-density
surface electromyographic (EMG) recordings of synergistic
muscles in the thigh demonstrate both shared synaptic drive
amongst the neural inputs within the synergistic group as well
as synaptic control specific to a muscle, depending on the
frequency of the neural drive (91). This synchrony between
spinal motor neurons and muscles involved in movement starts
manifesting itself during neonatal development (92). While
there are common inputs controlling groups of motor neurons
to produce movement, there is not complete concordance
between motor neuron input and muscle anatomy (93). This
incomplete concordance suggests non-linearity and multiscaling properties of complex adaptive systems.
Disease states, like adult-onset MNDs and aging, arise
from the breakdown of the structures underpinning physiologic
complexity (Figure 1B) (94, 95). One manifestation of this
breakdown of physiological complexity may be spontaneous
or induced discharges of hyperexcitable motor units known as
fasciculations (96). Fasciculations have been observed in adults
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Therapeutics options for early-onset MNDs are limited and
have focused on targeted replacement of the specific MNDassociated gene that is lost or mutated. While these targeted
therapeutic replacement strategies have significantly improved
the quality of life for patients with early-onset MNDs, treated
individual still have a partial disease phenotype. As early-onset
MNDs can be considered complex adaptive systems, therapeutic
agents that target another component of the motor unit–aside
from the one lost by genetic mutations–could provide significant
therapeutic benefit (Figure 1C). There is mounting evidence
demonstrating the efficacy of SMN-independent targets for
SMA (106) and, by extension, other early-onset motor neuron
diseases. These neuroprotective agents have multiple targets
for their therapeutic benefits. The development of therapeutic
strategies to manage epilepsy demonstrates the value of multitarget therapeutic strategies to treat neurological diseases (107).
As examples of multi-target therapies for motor neuron diseases,
we will describe two neuroprotectants that have shown strong
in vivo efficacy in different types of motor neuron diseases: 4phenylbutyrate (4PBA) and inhibitors of histone deacetylase 6
(HDAC6) (Table 1).
4PBA is one of the first multimodal therapeutics proposed
from multiple motor neuron diseases. In SMA, early studies
demonstrated that 4PBA increases SMN2 expression in SMA
patient-derived cells (109, 110), Administration of 4PBA to
SMN17 SMA mice resulted in a significant improvement in
survival and motor function (108). As 4PBA was approved
for treating humans, pilot clinical trials for 4PBA in SMA
was completed with modest ameliorative effects in patients
(112, 113). These studies did not detect any significant changes
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TABLE 1 Summary of 4-PBA and HDAC6 inhibitors demonstrating therapeutic beneﬁt in model systems for early-onset motor neuron diseases.

Compound

Disease model

Effect

Reference(s)

4-PBA

SMN17 mouse

Improvement in survival and phenotype

(108)

4-PBA

SMA patient-derived fibroblasts

Modest increase in FL-SMN expression;

(109–111)

interindividual variability
4-PBA

SMA patients

Modest improvement in motor function

4-PBA

SOD1 (G93A) mouse

Marked improvement in survival and motor

(112, 113)
(114)

function
4-PBA + riluzole

SOD1 (G93A) mouse

Additive ameliorative effects relative to 4PBA or

(115)

riluzole alone
4-PBA +

SOD1 (G93A) mouse

Additive ameliorative effects relative to 4PBA or

AEOL-10150

(116)

AEOL10150 alone

4-PBA

Postsymptomatic ALS patients

Improved motor function

(117)

4-PBA +

Postsymptomatic ALS patients

Additive ameliorative effected related to 4PBA

(118)

taurursodiol
Tubastatin A

alone
FUS (R521H) and FUS (P525L)

Improves motor neurite outgrowth and function

(119, 120)

TARDBP (A382T), TARDBP

Improves neurite outgrowth and mitochondrial

(121)

(G287S), and TARDBP (N390S)

transport along axons

cultured motor neurons (ALS6)
Tubastatin A

cultured motor neurons (ALS10)
Tubastatin A

HSPB1 (S135F) mouse (CMT2F)

Markedly improves motor neuron and muscle

(122)

innervation
Tubastatin A

GARS (R234KY) and Gars (C201R)

Improves motor function

(123)

GARS1 (P724H) cultured motor

Improves electrophysiologic misfiring and

(124)

neurons (CMT2D)

axonal transport defects

Gars knocked-down zebrafish

Improve deficient neurite outgrowth and

embryos

defective neuromuscular junction maturation

SW-100

MFN2 (R94Q) mouse (CMT2A1)

Improves motor phenotype

(126)

CKD-504

GARS1 (P724H) cultured motor

Improves electrophysiologic misfiring and

(124)

neurons (CMT2D)

axonal transport defects

Gars knocked-down zebrafish

Improve deficient neurite outgrowth and

embryos

defective neuromuscular junction maturation

FUS (R521H) and FUS (P525L)

Improves motor neurite outgrowth and function

(119)

Improves motor function and diminishes

(127)

mice (CMT2D)
Tubastatin A

Tubastatin A

CKD-504

ACY-738

(125)

(125)

cultured motor neurons
ACY-738

FUS overexpressing mice

neurodegeneration
ACY-738

HSPB1 (S135M) mice (CMT2F)

Improves survival and ameliorates the motor

(128, 129)

phenotype
T3796106

Cultured HSPB1 (S135M) CMT

Improves motor neuron phenotype

(130)

Improves motor neuron phenotype

(130)

motor neurons (CMT2F)
T3793168

Cultured HSPB1 (S135M) CMT
motor neurons (CMT2F)

in SMN2 expression in SMA patients treated with 4PBA.
Additional testing of patient-derived SMA cell lines showed
a high degree of interindividual variability in responsiveness
to 4PBA (111). In the SMN17 SMA mice, the protective
effects of 4PBA—as well as of other butyrate prodrugs–were
independent of SMN2 induction (108). 4PBA significantly
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improves motor dysfunction and increases lifespan in the
SOD1 (G93A) mouse model for ALS (114). In the same
ALS mouse model, 4PBA displayed additive effects when coadministered with other neuroprotectants–such as riluzole and
AEOL-10150–that have shown efficacy on the motor neurons
of ALS mice (115, 116). In a clinical trial, 4PBA improved
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motor outcomes in a cohort of ALS patients who received
the therapeutic after disease onset (117). Postsymptomatic
ALS patients showed some additive improvement in disease
progression when treated with 4PBA and taurursodiol (118).
Taken together, these studies demonstrate that 4PBA exerts
neuroprotective effects in genetically different forms of motor
neuron disease via an unknown mechanism, although we
anticipate that the mechanism is mediated through network
interactions. Furthermore, it is unclear at present if the
neuroprotective mechanisms are disease-specific or share a
common modality.
HDAC6 is highly expressed in the central nervous system
and functions by removing acetyl groups from a variety
of proteins aside from histones (131). HDAC6 has been
implicated in the pathogenesis of many neurodegenerative
diseases. Inhibitors of HDAC6 have demonstrated efficacy in
ameliorating disease phenotypes in multiple motor neuron
diseases. Ablation of Hdac6 in transgenic mice harboring
the ALS-linked SOD1 (G93A) mutation improves motor
phenotype as well as increases lifespan in these mice (132).
Tubastatin A and ACY-738 improve neurite outgrowth and
motor neuron function in ALS-linked mutant FUS [FUS
(R521H) and FUS (P525L)] motor neurons (119). Tubastatin
A improves motor neuron function in ALS-linked FUS
[FUS (R521H) and FUS (P525L)] motor neurons cultured
in microfluidic devices (120). ACY-738 ameliorates the
motor neuron degeneration observed in transgenic mice
overexpressing wild-type FUS (127). Tubastatin A improves
neurite outgrowth in patient-derived cultured motor neurons
harboring different ALS-associated TDP43 mutations [TARDBP
(A382T); TARDBP (G287S) and TARDBP (N390S)] (121).
The subcellular distribution of mutant TDP-43 as well
as mitochondrial transport along axons were restored by
tubastatin A.
In addition to exerting neuroprotective effects in model
systems for ALS, HDAC6 inhibitors have been shown to
ameliorate motor neuronopathy phenotypes observed in
multiple types of axonal peripheral neuropathies, i.e., type
2 CMT. The HDAC6-selective inhibitor SW-100 improves
motor phenotype in MFN2 (R94Q) mouse model for
CMT2A1 (126). Tubastatin A markedly improves motor
neuron and muscle innervation in the HSPB1 (S135F)
mouse model for CMT2F (122). ACY-738 improves survival
and ameliorates the motor phenotype observed in CMT2F
[HSPB1 (S135M)] mice (128, 129). HDAC6 inhibition
via the novel small molecules T3796106 and T3793168
improves motor neuron phenotype in cultured HSPB1
(S135M) CMT motor neurons (130). Tubastatin A improves
motor function in the mutant GARS (R234KY) as well as in
Gars (C201R) transgenic mouse models for CMT2D (123).
Electrophysiologic misfiring and axonal transport defects are
corrected in CMT2D motor neurons by tubastatin A and
CKD-504 (124). Tubastatin A and CKD-504 improve deficient
neurite outgrowth and defective neuromuscular junction
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maturation that are observed in zebrafish embryos where Gars
is knocked down with splice-blocking antisense morpholino
oligonucleotides (125).
Combinatory therapeutics have shown promise in animal
models for SMA. One of the first examples of a combinatory
therapeutic strategy demonstrated additive benefit was
treatment of SMA mice with a small-molecule inducer of SMN2
expression (D156844) alongside a myoprotectant (follistatin)
(133). Coadministration of a SMN2 exon 7 splice-correcting
oligonucleotide and RG7800–a small molecule that promotes
exon 7 inclusion–provided more pronounced additive effects
in SMA mice (134). In addition, combinatory, multi-target
therapies using a SMN2 exon 7 targeted splice correcting
antisense oligonucleotide alongside either a broad spectrum
histone deacetylase inhibitor (135) or a protein stabilizing
agent (136) have shown additive benefits in cell culture
and mouse models for SMA. The compounds described
previously (4PBA and HDAC6 inhibitors) could potentially
be considered as multi-target and multi-modal therapies
for MNDs.

Conclusions and future directions
Lower motor neurons and their connections to skeletal
muscles as well as to interneurons–or the motor unit–can
be thought of as a network of agents (genes, metabolites
and activities) organized into aggregate clusters that interact
with each other non-linearly in a hierarchical organization.
These agents and their interactions have distinct, adaptable
specializations that respond to selective environmental pressure.
The complex adaptive system mediates the flow of information
or materials from the external input from the lower motor
neuron to the neuromuscular junction. Early-onset MNDs can
be viewed as consequences of a breakdown of complexity
within the motor unit network. A genetic perturbation within
an agent in this network would pathologically alter the entire
network and the flow of information from the input to
the output.
Current strategies for therapeutics development for
early-onset MNDs focus on amelioration or replacement
of a single perturbation. This reductionist approach has
been successful in improving the quality of life and
disease presentation in SMA by SMN replacement. While
very successful, targeted SMN replacement therapy has
provided variable therapeutic benefit within the SMA
patient population. Using a complex system approach to
understand early-onset MNDs would provide a path for
better understanding how loss of a specific agent affects the
entire motor system network as well as multiple avenues
for therapeutic interventions. These neuroprotective
interventions potentially would provide therapeutic
benefit for many early-onset MNDs as opposed to a single
genetic disorder.
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